KPV

This combined in vitro and in vivo study examined how the alpha-MSH-derived tripeptide KPV reaches intestinal epithelial and immune cells and what happens once it does. In Caco2-BBE and HT29-Cl.19A intestinal epithelial cell lines and in primary human T cells, KPV was taken up via the di/tripeptide transporter PepT1. Inside the cell, KPV inhibited activation of NF-κB and MAP kinase pathways and reduced secretion of pro-inflammatory cytokines including IL-6, IL-8, and IL-1β. In two murine colitis models — DSS-induced colitis and CD4+CD45RB-high T-cell transfer colitis — orally administered KPV was associated with reduced histological inflammation, lower myeloperoxidase activity, and decreased pro-inflammatory cytokine expression in colonic tissue. Effects required PepT1 expression, consistent with the proposed transporter-mediated uptake mechanism.

Researchers wanted to know how a small fragment of a natural anti-inflammatory hormone gets into gut cells and what it does there. They found that KPV hitches a ride on a transporter called PepT1 that intestinal cells already use to absorb small peptides from food. Once inside, KPV turned down the master inflammatory switch (NF-κB) and reduced the inflammatory signals the cell sends out. In two different mouse models of colitis, giving KPV by mouth was associated with less gut inflammation. Because PepT1 levels go up in inflamed intestine, KPV may be preferentially taken up exactly where it is needed.

This follow-up study extended the PepT1/KPV axis from acute colitis into a model of colitis-associated cancer (azoxymethane plus DSS in mice). Intestinal-epithelium-specific PepT1 knockout reduced tumor burden, indicating a role for the transporter in inflammation-driven tumorigenesis. In wild-type animals, oral administration of KPV via nanoparticle delivery was associated with reductions in colonic tumor number and size, decreased proliferative index, and lower expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) in colonic tissue. The authors interpret the data as consistent with KPV exerting an anti-inflammatory effect at the epithelium through PepT1-mediated uptake and downstream NF-κB modulation.

Long-term gut inflammation can drive cancer in mouse models. This study asked whether the same transporter that brings KPV into gut cells also plays a role in inflammation-related tumors — and whether KPV could push back. Researchers found that mice lacking PepT1 in their gut lining developed fewer tumors, and that giving KPV by mouth was associated with smaller and fewer tumors plus lower inflammatory signals. The findings reinforce the idea that KPV's effects in the gut work through the PepT1 transporter and the NF-κB inflammatory pathway.